Volume 27, Number 5—May 2021
Research
Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands
Table 1
Characteristic | Value |
---|---|
Total | 970 |
Median age, y (range) |
42 (18–86) |
Sex | |
M | 435 (44.8) |
F | 525 (54.1) |
Unknown |
10 (1.1) |
Symptoms reported |
886 (91.3) |
Days after symptom onset, median (no. cases/total no. tested) | 4 (725/970) |
0–3 | 319 (44.0) |
4–7 | 331 (45.7) |
>8 |
75 (10.3) |
Positivity by PCR | 186 (19.2) |
PCR Ct E gene, median (range) | 23.6 (15.6–37.4) |
Ct >35 | 1 (0.5) |
Ct >30 | 28 (15.1) |
Ct <30 | 159 (85.5) |
Ct <25 | 113 (60.8) |
Ct <20 | 31 (16.7) |
*Values are no. (%) except as indicated. E gene, envelope gene; Ct, cycle threshold.
Page created: March 16, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.